ANGLE PLC LS-,10

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
00857U107
SEDOL
3433067
CIK
N/A
angleplc.com
LEI:
FIGI: BBG000QY3TF3
AGL
ANGLE PLC LS-,10
GICS: - · Sector: Health Care · Sub-Sector: Health Care
NAME
ANGLE PLC LS-,10
ISIN
GB0034330679
TICKER
AGL
MIC
AIMX
REUTERS
AGL.L
BLOOMBERG
AGL LN
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants

The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by AccessWire.

Fri, 15.11.2024       ANGLE
GB0034330679

CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer patients and may help to advance personalised treatment GUILDFORD, UNITED KINGDOM / ACCESSWIRE / November 15, 2024 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug d...
Read More
ANGLE
Technical Analysis Termsheet Terminal
Permalink
Fri, 15.11.2024       ANGLE
GB0034330679

RESULTS FROM WORK TO DEVELOP A PARSORTIX-BASED Her2 assay KIT SHOWCASED AT INTERNATIONAL LIQUID BIOPSY CONFERENCEParsortix-based HER2 kit being developed to provide an optimised, easily implemented, solution to enable product customers to undertake longitudinal, repeat assessment of HER2 status in breast cancerGUILDFORD, SURREY / ACCESSWIRE / Novem...
Read More
ANGLE
Technical Analysis Termsheet Terminal
Permalink
Wed, 13.11.2024       ANGLE
GB0034330679

PARSORTIX-BASED ASSAYS SHOWCASED AT THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH LIQUID BIOPSIES CONFERENCETwo posters highlight the importance of epitope-independent CTC enrichment and molecular characterisation of CTCs GUILDFORD, SURREY / ACCESSWIRE / November 13, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with...
Read More
ANGLE
Technical Analysis Termsheet Terminal
Permalink
Mon, 11.11.2024       ANGLE
GB0034330679

ANGLE plc ("the Company")DNA ANALYSIS OF PARSORTIX-ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIBThe addition of CTC-DNA analysis to clinical trials could identify patients developing treatment resistance prior to disease progressionCTC analysis identifies druggable targ...
Read More
ANGLE
Technical Analysis Termsheet Terminal
Permalink
Thu, 17.10.2024       ANGLE
GB0034330679

PUBLICATION DEMONSTRATES POTENTIAL FOR multi-marker CTC profiling IN EARLY PROSTATE CANCERParsortix enriched CTCs detected at high rates in localised diseaseMulti-marker profiling of CTCs could support development of targeted therapies and help stratify patients in clinical trials GUILDFORD, SURREY / ACCESSWIRE / October 17, 2024 / ANGLE plc (AIM:A...
Read More
ANGLE
Technical Analysis Termsheet Terminal
Permalink
Thu, 26.09.2024       ANGLE
GB0034330679

GUILDFORD, SURREY / ACCESSWIRE / September 26, 2024 / Whole Genomic Sequencing and machine learning identifies key cancer genes associated with DNA proliferation and repairANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical...
Read More
ANGLE
Technical Analysis Termsheet Terminal
Permalink
Thu, 26.09.2024       ANGLE
GB0034330679

Interim Results for the six months ended 30 June 2024LARGE PHARMA STRATEGY IMPLEMENTED SUCCESSFULLYThree Large Pharma contracts secured each with substantial revenue potentialStrategic decision post period end to focus resources on pharma services GUILDFORD, SURREY / ACCESSWIRE / September 26, 2024 / ANGLE plc ("ANGLE" or "the Compan...
Read More
ANGLE
Technical Analysis Termsheet Terminal
Permalink
Mon, 23.09.2024       ANGLE
GB0034330679

ANGLE ANNOUNCES NEXT GENERATION SEQUENCING ASSAY AGREEMENT WITH NUPROBEOption for exclusive licence to highly sensitive NGS assay for use with CTCs and dual analysis of CTCs with ctDNACombining the Parsortix system with comprehensive DNA molecular analysis opens up a broad range of pharma services opportunities GUILDFORD, SURREY / ACCESSWIRE / Sept...
Read More
ANGLE
Technical Analysis Termsheet Terminal
Permalink
Thu, 19.09.2024       ANGLE
GB0034330679

New pharma agreement for Parsortix CTC analysisGUILDFORD, SURREY / ACCESSWIRE / September 19, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce that it has signed an agreement with ...
Read More
ANGLE
Technical Analysis Termsheet Terminal
Permalink
Tue, 17.09.2024       ANGLE
GB0034330679

Notice of Interim Results and Webcast GUILDFORD, SURREY / ACCESSWIRE / September 17, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, will be releasing its interim results for the six months ended 30 Jun...
Read More
ANGLE
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements